Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Vertex (VRTX) is a Clean Revenue Growth Story, Pipeline is Discounted and Stock Remains Preferred - BMO Capital
January 26, 2022 4:46 PM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $274.00 price target on Vertex (NASDAQ: VRTX), following recent earnings report.
The analyst quotes: "Bottom line with Vertex is that, while there's been some pipeline challenges (before the positive 147 update), we... More
